A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated With a Trigger

Grants and Contracts Details

StatusFinished
Effective start/end date7/31/21 → 5/2/23

Funding

  • Alexion Pharmaceuticals: $38,860.00